Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
None
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous

  • 1 views
  • 24 Jan, 2021
  • 1 location
None
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

daratumumab to increase efficacy and improve outcomes of patients in both the relapse refractory and newly diagnosed settings. Two large Phase 2 trails using lenalidomide and dexamethasone or bortezomib and

lenalidomide
dexamethasone
daratumumab
bortezomib
neutrophil count
  • 15 views
  • 24 Jan, 2021
  • 2 locations
None
Daratumumab Ixazomib & Dexamethasone or Daratumumab Bortezomib & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with

calcium
dexamethasone
bortezomib
bone lesion
monoclonal protein
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

will be specifically targeted by a substance called bortezomib. The trial addresses patients with severe autoimmune encephalitis. The aim of the trial is to evaluate the efficacy and safety of

  • 1 views
  • 19 Feb, 2021
  • 13 locations
None
Metformin Nelfinavir and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of metformin and nelfinavir in combination with bortezomib in treating patients with multiple myeloma that has come back or does not

nelfinavir
refractory multiple myeloma
bortezomib
electrophoresis
tumor cells
  • 0 views
  • 13 Oct, 2021
  • 2 locations
None
Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

(500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The treatment course would be repeated three months later.

prednisone
treatment regimen
  • 2 views
  • 21 Oct, 2021
  • 1 location
None
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma

  • 0 views
  • 23 Jan, 2021
  • 1 location
None
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

cyclophosphamide , tacrolimus, mycophenolate . Recently Bortezomib has also been shown to inhibit dendritic cells maturation and function and possesses a number of other favorable immunomodulatory effect that can

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive

maintenance therapy
lenalidomide
dexamethasone
progressive disease
bortezomib
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) for NDMM NTE

This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed

dexamethasone
bortezomib
  • 0 views
  • 31 Jul, 2021
  • 4 locations